Progressive retinal atrophy (PRA) in dogs is a genetic condition, which means it cannot be prevented through diet, lifestyle, or environmental changes once a dog carries the causative mutations. The only reliable way to prevent PRA is to stop affected genes from being passed to the next generation through genetic testing and responsible breeding. If your dog already has PRA, there is no cure, but early detection and supportive care can help you manage the transition to vision loss.
Why PRA Cannot Be Prevented After Birth
PRA is not one disease but a group of inherited retinal degenerations caused by mutations in different genes. More than 100 dog breeds are affected. The vast majority of PRA forms are autosomal recessive, meaning a dog needs to inherit a defective copy of the gene from both parents to develop the disease. Some rarer forms follow dominant or X-linked inheritance patterns, but the principle is the same: the disease is written into the dog’s DNA before birth.
Because the underlying cause is genetic, no supplement, medication, or training protocol will stop PRA from developing in a dog that carries two copies of a causative mutation. The photoreceptor cells in the retina (the rods and cones responsible for vision) will degenerate on a timeline dictated by which specific mutation the dog carries. In early-onset forms, like rod-cone dysplasia in Irish Setters or Cardigan Welsh Corgis, blindness can occur in young adults. In late-onset forms, like progressive rod-cone degeneration (prcd), dogs develop normally and lose vision gradually in middle age.
Genetic Testing Is the Primary Prevention Tool
DNA testing before breeding is the single most effective way to prevent PRA in future litters. The most widely tested mutation is prcd, caused by a single nucleotide change in the PRCD gene. Labs like the UC Davis Veterinary Genetics Laboratory offer prcd panels for Golden Retrievers, Labrador Retrievers, Nova Scotia Duck Tolling Retrievers, and other at-risk breeds. Breed-specific tests also exist for mutations like rcd1 in Irish Setters, rcd2 in Collies, rcd3 in Cardigan Welsh Corgis, and rcd4 in Gordon Setters.
A DNA test will classify your dog into one of three categories:
- Clear (no copies): The dog does not carry the mutation and will not develop that form of PRA.
- Carrier (one copy): The dog will not develop PRA but can pass the mutation to offspring.
- Affected (two copies): The dog will develop PRA.
The practical rule for breeders is straightforward: never breed two carriers together. A carrier can be safely bred to a clear dog, since none of the puppies will be affected (though some will be carriers). This approach lets breeders maintain genetic diversity in their lines while eliminating the disease. Breeding two carriers together gives each puppy a 25% chance of being affected.
One important caveat: researchers have not yet discovered every mutation that causes PRA. A dog can test clear for all known variants and still develop PRA from an undiscovered mutation. This is why genetic testing works best alongside clinical eye exams.
Annual Eye Exams for Breeding Dogs
The American College of Veterinary Ophthalmologists (ACVO) recommends annual ophthalmic exams for all dogs in active breeding lines, regardless of breed. These exams are registered through the Companion Animal Eye Registry (CAER), operated jointly by the ACVO and the Orthopedic Foundation for Animals (OFA). A clinical diagnosis of PRA results in an unequivocal “no” breeding recommendation, meaning the dog should be removed from any breeding program.
The reason annual exams matter is that many forms of PRA are not congenital. A dog may pass an eye exam at age two and develop detectable changes at age five. Serial exams increase the chance of catching the disease before an affected dog has been bred multiple times. A specialized test called electroretinography (ERG) can detect retinal dysfunction even earlier than a standard eye exam. In Miniature Schnauzers, for example, ERG recordings have shown functional deficits as early as 8 weeks of age, well before any visible changes appear on a routine exam.
Breeds at Highest Risk
If you own or are considering purchasing a dog from a breed with known PRA prevalence, genetic testing becomes especially important. Breeds with well-documented PRA mutations include Labrador Retrievers, Golden Retrievers, Cocker Spaniels, Miniature Schnauzers, Irish Setters, Gordon Setters, Cardigan Welsh Corgis, Norwegian Elkhounds, Tibetan Spaniels, Tibetan Terriers, Papillons, Basenjis, Schapendoes, and Sloughis. Spitz-type dogs also show significant prevalence, with mutations in the Phosducin gene linked to a late-onset form diagnosed in middle-aged dogs.
When buying a puppy from any of these breeds, ask the breeder for documentation of both parents’ genetic test results and CAER eye exam certifications. A responsible breeder will have this information readily available. The ACVO genetics committee maintains a document called “The Blue Book,” available online through both acvo.org and ofa.org, which lists known and presumed inherited eye conditions by breed.
Recognizing Early Signs
If prevention through breeding was not possible and your dog may be at risk, early recognition helps you prepare. The first symptom of PRA is almost always night blindness. Your dog may hesitate at doorways in dim light, bump into furniture in darkened rooms, or become reluctant to go outside at night. This happens because rod cells, which handle low-light vision, typically degenerate before cone cells.
As the disease progresses, daytime vision deteriorates as well. You may notice dilated pupils, increased reflectivity (a greenish shine) from the eyes, and eventually cataract formation. The timeline varies dramatically depending on the mutation. Early-onset forms can cause noticeable vision problems in puppies or young adults. Late-onset prcd may not show symptoms until a dog is five to seven years old or older.
Can Anything Slow Down Vision Loss?
No proven treatment stops PRA progression in dogs, but there is some evidence that antioxidant supplementation supports retinal health more broadly. A study testing a daily antioxidant blend (lutein, zeaxanthin, beta-carotene, astaxanthin, and vitamins C and E) found that supplemented dogs had measurably improved retinal responses on electroretinography and slower age-related changes in visual function over a six-month period. This research focused on general age-related retinal decline rather than PRA specifically, so it should not be interpreted as a PRA treatment. Still, maintaining overall retinal health through nutrition is unlikely to cause harm and may offer modest support.
Gene therapy represents the most promising avenue for actual treatment. Research in dog models of PRA has been instrumental in developing gene therapies now used in humans. Studies in Briard dogs with a mutation in the RPE65 gene led directly to human clinical trials for childhood blindness. Gene therapy has also shown success in dog models involving other PRA-related mutations. These therapies are not yet commercially available for pet dogs, but the underlying science is advancing steadily.
What You Can Do Right Now
If you are a breeder, test every dog in your program for breed-relevant PRA mutations and schedule annual CAER eye exams. Never breed a dog that has been clinically diagnosed with PRA, and avoid pairing two carriers. If you are buying a puppy from a high-risk breed, request genetic test results and eye certifications for both parents before committing.
If your dog has already been diagnosed with PRA, focus on making your home environment safe and predictable. Dogs adapt remarkably well to blindness when their surroundings stay consistent. Keep furniture in the same place, use textured mats to mark transitions between rooms, and introduce verbal cues and scent markers for navigation. Most dogs with PRA live full, comfortable lives once they and their owners adjust to the change.